COPD vs Asthma: Key Differences and Overlap Syndrome

What causes each condition?

Asthma is driven by chronic airway inflammation, often allergic in nature. The immune system over-responds to triggers — dust mites, pollen, pet dander, cold air, exercise, or smoke — causing the airway muscles to tighten and the lining to swell. The key feature is that this narrowing is largely reversible, either spontaneously or with bronchodilator treatment 1Ref 1Global Initiative for Asthma (GINA) Science Committee (2024).Global Strategy for Asthma Management and Prevention.Asthma definition, reversible airflow obstruction, and asthma-COPD overlap characteristics.

COPD results from long-term injury to lung tissue and airways, most commonly from cigarette smoking, though occupational dust and indoor biomass fuel smoke are also important causes. The damage is structural and largely permanent: the small airways scar and collapse (obstructive pattern), and in emphysema, the alveolar air sacs break down. The result is airflow obstruction that does not fully reverse with a bronchodilator 2Ref 2Global Initiative for Chronic Obstructive Lung Disease (2024).Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report).COPD definition, spirometric criteria (post-bronchodilator FEV1/FVC < 0.70), and distinction from asthma3Ref 3Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. (2023).Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.COPD diagnostic approach, spirometry criteria, and treatment framework.

In practice, age is often the first clue: asthma typically begins in childhood or young adulthood, while COPD usually emerges after age 40 in people with significant smoking history.

How do the symptoms compare?

Both conditions cause: - Shortness of breath - Wheezing - Chest tightness - Cough

The pattern differs, though. In asthma, symptoms are typically episodic — they come and go, triggered by specific exposures or time of day (often worse at night or early morning), and return to near-normal between episodes. In COPD, breathlessness tends to be persistent and progressive, worsening with exertion. Morning cough with mucus production is a hallmark of chronic bronchitis, a COPD subtype.

Exacerbations — acute worsening episodes — occur in both conditions but are especially consequential in COPD, where each severe episode can accelerate lung function decline.

How does a clinician tell them apart?

The main diagnostic tool is spirometry — a breathing test that measures how fast and how much air you can exhale. The critical finding in COPD is a post-bronchodilator FEV1/FVC ratio below 0.70, meaning that obstruction persists even after inhaling a bronchodilator. In asthma, the obstruction typically reverses significantly after bronchodilator use 2Ref 2Global Initiative for Chronic Obstructive Lung Disease (2024).Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report).COPD definition, spirometric criteria (post-bronchodilator FEV1/FVC < 0.70), and distinction from asthma3Ref 3Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. (2023).Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.COPD diagnostic approach, spirometry criteria, and treatment framework.

Beyond spirometry, the clinician looks at:

• Age at onset and smoking history — COPD almost always requires years of smoking (or equivalent exposure); childhood asthma has no such prerequisite.
• Symptom variability — significant day-to-day or hour-to-hour variation strongly suggests asthma.
• Allergy history and triggers — a classic allergic history (hay fever, eczema, family history of atopy) points toward asthma.
• Blood eosinophil count — elevated eosinophils suggest eosinophilic inflammation, which is more common in asthma and some forms of COPD.
• Chest imaging — emphysema shows characteristic changes on CT; asthma typically does not.

These features together form a clinical picture that spirometry alone cannot always resolve.

What is asthma-COPD overlap (ACO)?

Some people — particularly long-term smokers who also have a history of childhood asthma or strong allergic tendencies — have features of both diseases at once. This is called asthma-COPD overlap (ACO). It is not a separate disease but a descriptive label for a pattern of overlapping characteristics.

People with ACO tend to have more frequent exacerbations and a greater burden of respiratory symptoms than those with either condition alone. They often respond well to inhaled corticosteroids because of the eosinophilic component, even though COPD alone does not always warrant that treatment 1Ref 1Global Initiative for Asthma (GINA) Science Committee (2024).Global Strategy for Asthma Management and Prevention.Asthma definition, reversible airflow obstruction, and asthma-COPD overlap characteristics2Ref 2Global Initiative for Chronic Obstructive Lung Disease (2024).Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report).COPD definition, spirometric criteria (post-bronchodilator FEV1/FVC < 0.70), and distinction from asthma.

Diagnosing ACO matters because it influences the treatment approach — typically a combination of bronchodilators and inhaled steroids — and because these patients benefit from monitoring by both a pulmonologist and, in some cases, an allergist-immunologist.

Does treatment differ?

Yes, meaningfully:

• Asthma is primarily treated with inhaled corticosteroids as the controller medication, plus short-acting bronchodilators for rescue. Biologic therapies targeting specific immune pathways (such as IL-5 or IgE) are available for severe allergic or eosinophilic asthma.
• COPD centers on long-acting bronchodilators (LABAs and LAMAs); inhaled corticosteroids are added only for specific patients, particularly those with frequent exacerbations and elevated eosinophils.
• ACO typically warrants an inhaled corticosteroid combined with one or more long-acting bronchodilators, reflecting features of both.

Using a LABA without an inhaled corticosteroid in someone with undiagnosed asthma can be unsafe — another reason why getting the diagnosis right matters. This distinction is best sorted out with a primary care clinician or pulmonologist, ideally with spirometry.

When should I see someone about my breathing?

If you have persistent shortness of breath, frequent coughing, or wheezing that is limiting your activities or happening more than twice a week, a clinical evaluation is worth seeking. Gale's primary care clinicians can take your history, order spirometry, and determine whether a pulmonologist or allergist referral is appropriate. Early diagnosis of either condition can prevent years of unnecessary limitation.